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captured using a sized-based microfilter and identified as nucleated, cytokeratin posi-
tive/CD45 negative cells. Resulting ctDNA z-scores were compared to tumor fractions
established with the recently published ichorCNA algorithm and associated with the
clinical outcome.
Results: We observed a close correlation between mFAST-SeqS z-scores and ichorCNA
ctDNA quantifications. Patients with mFAST-SeqS z-scores above three (34.5%)
showed significantly worse overall (p¼ 0.014) and progression-free survival
(p¼ 0.018) compared to patients with lower values. Elevated z-score values were clearly
associated with radiological proven progression. In contrast, baseline CTC count, CEA,
and CA15-5 had no prognostic impact on the outcome of patients in the analyzed
cohort.
Conclusions: This proof of principle study demonstrates the prognostic impact of
ctDNA levels detected with mFAST-SeqS as a very fast and cost-effective means to
assess the ctDNA fraction without prior knowledge of the genetic landscape of the
tumor. Furthermore, mFAST-SeqS-based ctDNA levels provided an early means of
measuring treatment response.
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Background: The identification of biomarkers to drive treatment is one of the most
important objectives of precision medicine. During last years, the role of PIK3CA
mutations have been related to clinical benefit deriving from treatment with PI3K, and
mTOR inhibitors. In breast cancer (BC), PIK3CA mutations are widely present and the
use, in clinical trials, of selective inhibitors improved clinical outcomes. The aim of this
study is to assess the value of a monocentric genomic screening program to select
patients for trials with experimental targeted agents.
Methods: We examined PIK3CA mutation in a cohort of 312 metastatic BC patients
diagnosed at Hospital Clınico València-INCLIVA from Jan-13 to Apr-19. The sequenc-
ing of hotspot mutations was performed in primary (29.9%) and metastatic tissue
(70.1%). We used two different technologies: MassARRAY technology (Sequenom
MassARRAY, OncoCarta v1.0) and Iluminia MiSeq System (customised panel,
OncoSpot v.1). Hotspots were selected according to databases already published. To be
diagnosed as mutated, tumors needed to harbor at least 5% of mutant alleles. 7 clinical
trials against PI3K pathway were available.
Results: PIK3CA analysis was performed in 312 paraffin embedded tumor samples, in
which only 5.8% the analysis was not possible due to low quality of DNA. The distribu-
tion of BC subtypes were 77.6% Luminal, 13.9% HER2, and 8.5% triple negative (TN).
PIK3CA mutations were detected in 96 patients (32.7%). In Luminal, PIK3CA muta-
tions reached 36.8% while only 19.5% in HER2 and 16.0% in TN, respectively. A wide
spectrum of PIK3CA mutations was found: H1047R (38.5%), E545K (30.2%), E542K
(19.8%), R88Q (3.1%), M1043I (3.1%), N345K (2.1%), P539R (1.0%), K111E (1.0%),
C420R (1.0%). One hundred and ninety (64.6%) patients were included in clinical tri-
als, and 74 (38.9%) were treated with PI3K, AKT and mTOR inhibitors.
Conclusions: PIK3CA mutations were widely present among luminal BC, being
actually a specific target for new drugs. PIK3CA mutational analysis was easily and suc-
cessfully performed in our center. The identification of PIK3CA hotspots mutations
lead to the access for our patient to novel drugs into clinical trials, achieving relevant
clinical benefits in most of the cases.
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M. Mallafré-Larrosa1, T. Pascual1, N. Chic2, O. Martınez2, P. Galvan1, B. Gonzalez-Farre3,
M. Vidal2, M. Mu~noz2, B. Adamo2, A. Prat2
1Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut
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Background: The incidence of BCBM is increasing as a result of both improved diag-
nostic techniques and longer survival due to better treatment approaches. However, it
is still a challenging situation occasioned by the poor responses to different standard
therapies, representing an unmet medical need. Determining the molecular profile may
be clinically relevant in order to improve the outcome of our patients (pts).
Methods: This is an observational retrospective study including BC-pts who had
undergone surgery of BCBM in Hospital Clinic (Barcelona, Spain) between January
2000 and December 2017. RNA was isolated from FFPE tumor tissue and the expres-
sion of 55 BC-related genes was assessed on the nCounter. Median progression free sur-
vival (mPFS) and overall survival (mOS) were calculated using the Kaplan-Meier
method. The association of the expression of each gene with mPFS was evaluated using
univariate Cox-models. The same gene expression assay was tested BCBM-paired pri-
mary tumor samples.
Results: 20 pts with resected BMBC were included. Median age at diagnosis of BCBM
was 57.8years (y). mOS from diagnosis of BCBM was 20.22 months (range, 0.67-
64.50months). The intrinsic subtype distribution was 45% Basal-like, 20% HER2-
enriched (HER2-E), 10% Luminal A, 20% Luminal B and 5% Normal-like. High
expression of ESR1and PGR (determined as above the median) and low expression of
MKI67were related with better mOS (p¼ 0.008, p¼ 0.038 and p¼ 0.0165). 9 matched-
paired samples of primary BC and BCBM were analyzed and 4 (44.4%) PAM50 discor-
dances (2 Luminal B shifted to Luminal A, 1 Normal-like to Basal-like and 1 HER2-E to
Luminal B) were observed. Finally, down-regulation of CD8Aand PDL1expression
between primary and BCBM (p¼ 0.0234 and p¼ 0.0367, respectively) was observed.
Conclusions: Non-luminal intrinsic subtypes are more prevalent in resected BCBM,
and gene expression might predict OS. Our data suggest that BCBM can elude the
immune surveillance through downregulation of immune genes leading to an immu-
nosuppressed environment. Our analysis shows the value of analyzing gene expression
both by cancer subtype and metastatic origin, but further characterization is needed.
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Background: Combined endocrine/targeted approaches have been investigated as first-
line treatment in hormone receptors positive metastatic breast cancer (BC).
Randomized trials showed that the addiction of CDK (cyclin-dependent kinase) 4/6
inhibitors to endocrine therapy (ET) increase progression free survival (PFS). Elderly
patients (aged>65 years) are under represented in most of the trials. Due to the multi-
morbidity and the major toxicity associated with the targeted agents, the combination
strategy in that subgroup is widely discussed. The present meta-analysis aimed to
understand the role of the new endocrine approaches in elderly women.
Methods: This meta-analysis included first line phase II/III randomized published trials
comparing ET to the experimental strategy. Trials with no data about hazard ratios
(HR) for PFS in the subgroup of patients aged> 65 years were excluded. The heteroge-
neity of the data was evaluated by Chi-square Q test and I2 statistic. Prospero registra-
tion number: CRD42019120215.
Results: 8 studies were included: 4 (Paloma1/TRIO-18, Paloma2, Monaleesa2,
Monarch3) investigated the role of CDK 4/6 inhibitors, 2 trials (SWOG and FACT)
analysed the combination of Fulvestrant plus Aromatase Inhibitors, while other two tri-
als explored the association of ET with Bevacizumab (LEA) and Temsirolimus
(HORIZON), respectively. Overall, the meta-analysis showed a PFS advantage for the
experimental arms [HR 0.77, p 0.016] with a significant high/moderate heterogeneity
[I2 65.46%, p 0.005]. The 4 studies adding CDK4/6 inhibitors to ET showed a signifi-
cant improvement in PFS compared to ET alone. No significant advantages for the
addition of anti-angiogenic agents or Fulvestrant to ET have been found.
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Conclusions: The novel experimental strategies showed an improvement in PFS in eld-
erly patients. Adding CDK4/6 inhibitors to ET significantly prolongs PFS as compared
to ET alone, the magnitude of PFS benefit is age-independent. To define the role of
novel agents, future trials should be designed taking in account not only the age, but
also adequate geriatric assessment and comorbidity status.
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Background: PIK3CA mutations occur in 40% of HRþ/HER2 breast cancers. In
the phase III SOLAR-1 study (NCT02437318), ALP (PI3Ka inhibitor)þ FUL signifi-
cantly prolonged progression-free survival vs placebo (PBO)þ FUL in patients (pts)
with HRþ/HER2 ABC, prior endocrine therapy, and PIK3CA mutations (HR 0.65;
P< 0.001; Andre F, et al. NEJM. 2019). We report pt management details of key AESIs
from SOLAR-1.
Methods: Pts received ALPþ FUL (n¼ 284) or PBOþ FUL (n¼ 287). Safety was
assessed per CTCAE v4.03 and regardless of PIK3CA mutation status. We evaluated
time to onset and management of key AESIs in patients receiving ALP.
Results: The median ALP treatment exposure was 5.5 mo. As previously reported, the
most common any-grade AESIs were hyperglycemia, diarrhea, and rash (Table). Rates
of ALP discontinuation and median times to onset and improvement are presented in
the table. Supportive medication was frequently used to manage hyperglycemia, diar-
rhea, and rash. In pts with anti-rash medication initiated prior to onset of rash
(n¼ 86), 60 (69.8%) received antihistamines. Use of anti-rash medication prior to
onset of rash was associated with decreased frequency of rash (26.7% vs 53.9% in the
overall population) and decreased reported grade (grade 3, 11.6% vs 20.1%). During
the study, the implementation of more detailed AE management guidelines decreased
treatment discontinuation due to any-grade AEs (29.2% vs 20.7%) and grade 3
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Pts with  grade-3 110 (38.7)d 19 (6.7) 28 (9.9)e
Clinical trial identification: NCT02437318.
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